data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,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India
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
––%
––%
––%
––%
––%
––%
CureVac NV
(NASDAQ:CVAC)
$11.06
-0.62[-5.31%]
At close: Feb 3
$11.06
After Hours: 4:35PM EDT
Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
JJ Kinahan - Sponsored
Vandana Singh - 6 days ago
ACCESSWIRE - 4 days ago
ACCESSWIRE - 5 days ago
ACCESSWIRE - 6 days ago
PRNewswire - Jan 19, 2023, 8:49AM
PRNewswire - Jan 10, 2023, 8:30AM
PRNewswire - Jan 9, 2023, 8:30AM
ACCESSWIRE - Jan 9, 2023, 7:15AM
ACCESSWIRE - Jan 6, 2023, 7:15AM
ACCESSWIRE - Dec 14, 2022, 4:25PM
ACCESSWIRE - Nov 16, 2022, 7:30AM
ACCESSWIRE - Nov 11, 2022, 7:20AM
ACCESSWIRE - Nov 10, 2022, 7:15AM
ACCESSWIRE - Aug 18, 2022, 7:40AM
ACCESSWIRE - Aug 18, 2022, 7:15AM
ACCESSWIRE - May 25, 2022, 7:55AM
ACCESSWIRE - May 25, 2022, 7:45AM
ACCESSWIRE - Apr 28, 2022, 7:50AM
ACCESSWIRE - Apr 22, 2022, 7:15AM
ACCESSWIRE - Apr 21, 2022, 7:15AM
ACCESSWIRE - Apr 11, 2022, 7:15AM
ACCESSWIRE - Mar 30, 2022, 7:15AM
ACCESSWIRE - Mar 1, 2022, 7:15AM
ACCESSWIRE - Feb 22, 2022, 7:00AM
ACCESSWIRE - Feb 10, 2022, 7:20AM
InvestorsObserver - 3 days ago
TipRanks - 5 days ago
InvestorsObserver - 5 days ago
InvestorsObserver - 6 days ago
TipRanks - 6 days ago
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 25, 2023, 2:44PM
TipRanks - Jan 23, 2023, 11:05AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorsObserver - Jan 19, 2023, 5:51AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
TipRanks - Jan 18, 2023, 12:25AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 1:16PM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
TipRanks - Jan 9, 2023, 8:38AM
TipRanks - Jan 9, 2023, 8:38AM
Seeking Alpha - Jan 9, 2023, 7:10AM
InvestorsObserver - Jan 9, 2023, 5:46AM
TipRanks - Jan 9, 2023, 2:32AM
TipRanks - Jan 9, 2023, 2:32AM
Seeking Alpha - Jan 6, 2023, 8:45PM
TipRanks - Jan 6, 2023, 1:40PM
TipRanks - Jan 6, 2023, 1:15PM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Read More

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
JJ Kinahan - Sponsored
Vandana Singh - 6 days ago
ACCESSWIRE - 4 days ago
ACCESSWIRE - 5 days ago
ACCESSWIRE - 6 days ago
PRNewswire - Jan 19, 2023, 8:49AM
PRNewswire - Jan 10, 2023, 8:30AM
PRNewswire - Jan 9, 2023, 8:30AM
ACCESSWIRE - Jan 9, 2023, 7:15AM
ACCESSWIRE - Jan 6, 2023, 7:15AM
ACCESSWIRE - Dec 14, 2022, 4:25PM
ACCESSWIRE - Nov 16, 2022, 7:30AM
ACCESSWIRE - Nov 11, 2022, 7:20AM
ACCESSWIRE - Nov 10, 2022, 7:15AM
ACCESSWIRE - Aug 18, 2022, 7:40AM
ACCESSWIRE - Aug 18, 2022, 7:15AM
ACCESSWIRE - May 25, 2022, 7:55AM
ACCESSWIRE - May 25, 2022, 7:45AM
ACCESSWIRE - Apr 28, 2022, 7:50AM
ACCESSWIRE - Apr 22, 2022, 7:15AM
ACCESSWIRE - Apr 21, 2022, 7:15AM
ACCESSWIRE - Apr 11, 2022, 7:15AM
ACCESSWIRE - Mar 30, 2022, 7:15AM
ACCESSWIRE - Mar 1, 2022, 7:15AM
ACCESSWIRE - Feb 22, 2022, 7:00AM
ACCESSWIRE - Feb 10, 2022, 7:20AM
InvestorsObserver - 3 days ago
TipRanks - 5 days ago
InvestorsObserver - 5 days ago
InvestorsObserver - 6 days ago
TipRanks - 6 days ago
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 25, 2023, 2:44PM
TipRanks - Jan 23, 2023, 11:05AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorsObserver - Jan 19, 2023, 5:51AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
TipRanks - Jan 18, 2023, 12:25AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 1:16PM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
TipRanks - Jan 9, 2023, 8:38AM
TipRanks - Jan 9, 2023, 8:38AM
Seeking Alpha - Jan 9, 2023, 7:10AM
InvestorsObserver - Jan 9, 2023, 5:46AM
TipRanks - Jan 9, 2023, 2:32AM
TipRanks - Jan 9, 2023, 2:32AM
Seeking Alpha - Jan 6, 2023, 8:45PM
TipRanks - Jan 6, 2023, 1:40PM
TipRanks - Jan 6, 2023, 1:15PM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Read More

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
JJ Kinahan - Sponsored
Vandana Singh - 6 days ago
ACCESSWIRE - 4 days ago
ACCESSWIRE - 5 days ago
ACCESSWIRE - 6 days ago
PRNewswire - Jan 19, 2023, 8:49AM
PRNewswire - Jan 10, 2023, 8:30AM
PRNewswire - Jan 9, 2023, 8:30AM
ACCESSWIRE - Jan 9, 2023, 7:15AM
ACCESSWIRE - Jan 6, 2023, 7:15AM
ACCESSWIRE - Dec 14, 2022, 4:25PM
ACCESSWIRE - Nov 16, 2022, 7:30AM
ACCESSWIRE - Nov 11, 2022, 7:20AM
ACCESSWIRE - Nov 10, 2022, 7:15AM
ACCESSWIRE - Aug 18, 2022, 7:40AM
ACCESSWIRE - Aug 18, 2022, 7:15AM
ACCESSWIRE - May 25, 2022, 7:55AM
ACCESSWIRE - May 25, 2022, 7:45AM
ACCESSWIRE - Apr 28, 2022, 7:50AM
ACCESSWIRE - Apr 22, 2022, 7:15AM
ACCESSWIRE - Apr 21, 2022, 7:15AM
ACCESSWIRE - Apr 11, 2022, 7:15AM
ACCESSWIRE - Mar 30, 2022, 7:15AM
ACCESSWIRE - Mar 1, 2022, 7:15AM
ACCESSWIRE - Feb 22, 2022, 7:00AM
ACCESSWIRE - Feb 10, 2022, 7:20AM
InvestorsObserver - 3 days ago
TipRanks - 5 days ago
InvestorsObserver - 5 days ago
InvestorsObserver - 6 days ago
TipRanks - 6 days ago
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 25, 2023, 2:44PM
TipRanks - Jan 23, 2023, 11:05AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorsObserver - Jan 19, 2023, 5:51AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
TipRanks - Jan 18, 2023, 12:25AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 1:16PM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
TipRanks - Jan 9, 2023, 8:38AM
TipRanks - Jan 9, 2023, 8:38AM
Seeking Alpha - Jan 9, 2023, 7:10AM
InvestorsObserver - Jan 9, 2023, 5:46AM
TipRanks - Jan 9, 2023, 2:32AM
TipRanks - Jan 9, 2023, 2:32AM
Seeking Alpha - Jan 6, 2023, 8:45PM
TipRanks - Jan 6, 2023, 1:40PM
TipRanks - Jan 6, 2023, 1:15PM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Read More

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
JJ Kinahan - Sponsored
Vandana Singh - 6 days ago
ACCESSWIRE - 4 days ago
ACCESSWIRE - 5 days ago
ACCESSWIRE - 6 days ago
PRNewswire - Jan 19, 2023, 8:49AM
PRNewswire - Jan 10, 2023, 8:30AM
PRNewswire - Jan 9, 2023, 8:30AM
ACCESSWIRE - Jan 9, 2023, 7:15AM
ACCESSWIRE - Jan 6, 2023, 7:15AM
ACCESSWIRE - Dec 14, 2022, 4:25PM
ACCESSWIRE - Nov 16, 2022, 7:30AM
ACCESSWIRE - Nov 11, 2022, 7:20AM
ACCESSWIRE - Nov 10, 2022, 7:15AM
ACCESSWIRE - Aug 18, 2022, 7:40AM
ACCESSWIRE - Aug 18, 2022, 7:15AM
ACCESSWIRE - May 25, 2022, 7:55AM
ACCESSWIRE - May 25, 2022, 7:45AM
ACCESSWIRE - Apr 28, 2022, 7:50AM
ACCESSWIRE - Apr 22, 2022, 7:15AM
ACCESSWIRE - Apr 21, 2022, 7:15AM
ACCESSWIRE - Apr 11, 2022, 7:15AM
ACCESSWIRE - Mar 30, 2022, 7:15AM
ACCESSWIRE - Mar 1, 2022, 7:15AM
ACCESSWIRE - Feb 22, 2022, 7:00AM
ACCESSWIRE - Feb 10, 2022, 7:20AM
InvestorsObserver - 3 days ago
TipRanks - 5 days ago
InvestorsObserver - 5 days ago
InvestorsObserver - 6 days ago
TipRanks - 6 days ago
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 25, 2023, 2:44PM
TipRanks - Jan 23, 2023, 11:05AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorsObserver - Jan 19, 2023, 5:51AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
TipRanks - Jan 18, 2023, 12:25AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 1:16PM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
TipRanks - Jan 9, 2023, 8:38AM
TipRanks - Jan 9, 2023, 8:38AM
Seeking Alpha - Jan 9, 2023, 7:10AM
InvestorsObserver - Jan 9, 2023, 5:46AM
TipRanks - Jan 9, 2023, 2:32AM
TipRanks - Jan 9, 2023, 2:32AM
Seeking Alpha - Jan 6, 2023, 8:45PM
TipRanks - Jan 6, 2023, 1:40PM
TipRanks - Jan 6, 2023, 1:15PM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Read More

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
JJ Kinahan - Sponsored
Vandana Singh - 6 days ago
ACCESSWIRE - 4 days ago
ACCESSWIRE - 5 days ago
ACCESSWIRE - 6 days ago
PRNewswire - Jan 19, 2023, 8:49AM
PRNewswire - Jan 10, 2023, 8:30AM
PRNewswire - Jan 9, 2023, 8:30AM
ACCESSWIRE - Jan 9, 2023, 7:15AM
ACCESSWIRE - Jan 6, 2023, 7:15AM
ACCESSWIRE - Dec 14, 2022, 4:25PM
ACCESSWIRE - Nov 16, 2022, 7:30AM
ACCESSWIRE - Nov 11, 2022, 7:20AM
ACCESSWIRE - Nov 10, 2022, 7:15AM
ACCESSWIRE - Aug 18, 2022, 7:40AM
ACCESSWIRE - Aug 18, 2022, 7:15AM
ACCESSWIRE - May 25, 2022, 7:55AM
ACCESSWIRE - May 25, 2022, 7:45AM
ACCESSWIRE - Apr 28, 2022, 7:50AM
ACCESSWIRE - Apr 22, 2022, 7:15AM
ACCESSWIRE - Apr 21, 2022, 7:15AM
ACCESSWIRE - Apr 11, 2022, 7:15AM
ACCESSWIRE - Mar 30, 2022, 7:15AM
ACCESSWIRE - Mar 1, 2022, 7:15AM
ACCESSWIRE - Feb 22, 2022, 7:00AM
ACCESSWIRE - Feb 10, 2022, 7:20AM
InvestorsObserver - 3 days ago
TipRanks - 5 days ago
InvestorsObserver - 5 days ago
InvestorsObserver - 6 days ago
TipRanks - 6 days ago
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 25, 2023, 2:44PM
TipRanks - Jan 23, 2023, 11:05AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorsObserver - Jan 19, 2023, 5:51AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
TipRanks - Jan 18, 2023, 12:25AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 1:16PM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
TipRanks - Jan 9, 2023, 8:38AM
TipRanks - Jan 9, 2023, 8:38AM
Seeking Alpha - Jan 9, 2023, 7:10AM
InvestorsObserver - Jan 9, 2023, 5:46AM
TipRanks - Jan 9, 2023, 2:32AM
TipRanks - Jan 9, 2023, 2:32AM
Seeking Alpha - Jan 6, 2023, 8:45PM
TipRanks - Jan 6, 2023, 1:40PM
TipRanks - Jan 6, 2023, 1:15PM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Read More

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
JJ Kinahan - Sponsored
Vandana Singh - 6 days ago
ACCESSWIRE - 4 days ago
ACCESSWIRE - 5 days ago
ACCESSWIRE - 6 days ago
PRNewswire - Jan 19, 2023, 8:49AM
PRNewswire - Jan 10, 2023, 8:30AM
PRNewswire - Jan 9, 2023, 8:30AM
ACCESSWIRE - Jan 9, 2023, 7:15AM
ACCESSWIRE - Jan 6, 2023, 7:15AM
ACCESSWIRE - Dec 14, 2022, 4:25PM
ACCESSWIRE - Nov 16, 2022, 7:30AM
ACCESSWIRE - Nov 11, 2022, 7:20AM
ACCESSWIRE - Nov 10, 2022, 7:15AM
ACCESSWIRE - Aug 18, 2022, 7:40AM
ACCESSWIRE - Aug 18, 2022, 7:15AM
ACCESSWIRE - May 25, 2022, 7:55AM
ACCESSWIRE - May 25, 2022, 7:45AM
ACCESSWIRE - Apr 28, 2022, 7:50AM
ACCESSWIRE - Apr 22, 2022, 7:15AM
ACCESSWIRE - Apr 21, 2022, 7:15AM
ACCESSWIRE - Apr 11, 2022, 7:15AM
ACCESSWIRE - Mar 30, 2022, 7:15AM
ACCESSWIRE - Mar 1, 2022, 7:15AM
ACCESSWIRE - Feb 22, 2022, 7:00AM
ACCESSWIRE - Feb 10, 2022, 7:20AM
InvestorsObserver - 3 days ago
TipRanks - 5 days ago
InvestorsObserver - 5 days ago
InvestorsObserver - 6 days ago
TipRanks - 6 days ago
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 25, 2023, 2:44PM
TipRanks - Jan 23, 2023, 11:05AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorsObserver - Jan 19, 2023, 5:51AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
TipRanks - Jan 18, 2023, 12:25AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 1:16PM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
TipRanks - Jan 9, 2023, 8:38AM
TipRanks - Jan 9, 2023, 8:38AM
Seeking Alpha - Jan 9, 2023, 7:10AM
InvestorsObserver - Jan 9, 2023, 5:46AM
TipRanks - Jan 9, 2023, 2:32AM
TipRanks - Jan 9, 2023, 2:32AM
Seeking Alpha - Jan 6, 2023, 8:45PM
TipRanks - Jan 6, 2023, 1:40PM
TipRanks - Jan 6, 2023, 1:15PM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Read More

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
JJ Kinahan - Sponsored
Vandana Singh - 6 days ago
ACCESSWIRE - 4 days ago
ACCESSWIRE - 5 days ago
ACCESSWIRE - 6 days ago
PRNewswire - Jan 19, 2023, 8:49AM
PRNewswire - Jan 10, 2023, 8:30AM
PRNewswire - Jan 9, 2023, 8:30AM
ACCESSWIRE - Jan 9, 2023, 7:15AM
ACCESSWIRE - Jan 6, 2023, 7:15AM
ACCESSWIRE - Dec 14, 2022, 4:25PM
ACCESSWIRE - Nov 16, 2022, 7:30AM
ACCESSWIRE - Nov 11, 2022, 7:20AM
ACCESSWIRE - Nov 10, 2022, 7:15AM
ACCESSWIRE - Aug 18, 2022, 7:40AM
ACCESSWIRE - Aug 18, 2022, 7:15AM
ACCESSWIRE - May 25, 2022, 7:55AM
ACCESSWIRE - May 25, 2022, 7:45AM
ACCESSWIRE - Apr 28, 2022, 7:50AM
ACCESSWIRE - Apr 22, 2022, 7:15AM
ACCESSWIRE - Apr 21, 2022, 7:15AM
ACCESSWIRE - Apr 11, 2022, 7:15AM
ACCESSWIRE - Mar 30, 2022, 7:15AM
ACCESSWIRE - Mar 1, 2022, 7:15AM
ACCESSWIRE - Feb 22, 2022, 7:00AM
ACCESSWIRE - Feb 10, 2022, 7:20AM
InvestorsObserver - 3 days ago
TipRanks - 5 days ago
InvestorsObserver - 5 days ago
InvestorsObserver - 6 days ago
TipRanks - 6 days ago
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 25, 2023, 2:44PM
TipRanks - Jan 23, 2023, 11:05AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorsObserver - Jan 19, 2023, 5:51AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
TipRanks - Jan 18, 2023, 12:25AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 1:16PM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
TipRanks - Jan 9, 2023, 8:38AM
TipRanks - Jan 9, 2023, 8:38AM
Seeking Alpha - Jan 9, 2023, 7:10AM
InvestorsObserver - Jan 9, 2023, 5:46AM
TipRanks - Jan 9, 2023, 2:32AM
TipRanks - Jan 9, 2023, 2:32AM
Seeking Alpha - Jan 6, 2023, 8:45PM
TipRanks - Jan 6, 2023, 1:40PM
TipRanks - Jan 6, 2023, 1:15PM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Read More

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
JJ Kinahan - Sponsored
Vandana Singh - 6 days ago
ACCESSWIRE - 4 days ago
ACCESSWIRE - 5 days ago
ACCESSWIRE - 6 days ago
PRNewswire - Jan 19, 2023, 8:49AM
PRNewswire - Jan 10, 2023, 8:30AM
PRNewswire - Jan 9, 2023, 8:30AM
ACCESSWIRE - Jan 9, 2023, 7:15AM
ACCESSWIRE - Jan 6, 2023, 7:15AM
ACCESSWIRE - Dec 14, 2022, 4:25PM
ACCESSWIRE - Nov 16, 2022, 7:30AM
ACCESSWIRE - Nov 11, 2022, 7:20AM
ACCESSWIRE - Nov 10, 2022, 7:15AM
ACCESSWIRE - Aug 18, 2022, 7:40AM
ACCESSWIRE - Aug 18, 2022, 7:15AM
ACCESSWIRE - May 25, 2022, 7:55AM
ACCESSWIRE - May 25, 2022, 7:45AM
ACCESSWIRE - Apr 28, 2022, 7:50AM
ACCESSWIRE - Apr 22, 2022, 7:15AM
ACCESSWIRE - Apr 21, 2022, 7:15AM
ACCESSWIRE - Apr 11, 2022, 7:15AM
ACCESSWIRE - Mar 30, 2022, 7:15AM
ACCESSWIRE - Mar 1, 2022, 7:15AM
ACCESSWIRE - Feb 22, 2022, 7:00AM
ACCESSWIRE - Feb 10, 2022, 7:20AM
InvestorsObserver - 3 days ago
TipRanks - 5 days ago
InvestorsObserver - 5 days ago
InvestorsObserver - 6 days ago
TipRanks - 6 days ago
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 25, 2023, 2:44PM
TipRanks - Jan 23, 2023, 11:05AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorsObserver - Jan 19, 2023, 5:51AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
TipRanks - Jan 18, 2023, 12:25AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 1:16PM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
TipRanks - Jan 9, 2023, 8:38AM
TipRanks - Jan 9, 2023, 8:38AM
Seeking Alpha - Jan 9, 2023, 7:10AM
InvestorsObserver - Jan 9, 2023, 5:46AM
TipRanks - Jan 9, 2023, 2:32AM
TipRanks - Jan 9, 2023, 2:32AM
Seeking Alpha - Jan 6, 2023, 8:45PM
TipRanks - Jan 6, 2023, 1:40PM
TipRanks - Jan 6, 2023, 1:15PM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Read More

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

CureVac Stock (NASDAQ:CVAC), Quotes and News Summary

CureVac Stock (NASDAQ: CVAC) stock price, news, charts, stock research, profile.

Day Range11.010 - 11.83052 Wk Range5.630 - 20.500Open / Close11.470 / 11.060Float / Outstanding75.236M / 190.283M
Vol / Avg.537.147K / 959.793KMkt Cap2.105BP/E-50d Avg. Price8.460
Div / Yield (Forward)- / -%Payout Ratio-Total Float75.236MEPS-0.640
JJ Kinahan - Sponsored
Vandana Singh - 6 days ago
ACCESSWIRE - 4 days ago
ACCESSWIRE - 5 days ago
ACCESSWIRE - 6 days ago
PRNewswire - Jan 19, 2023, 8:49AM
PRNewswire - Jan 10, 2023, 8:30AM
PRNewswire - Jan 9, 2023, 8:30AM
ACCESSWIRE - Jan 9, 2023, 7:15AM
ACCESSWIRE - Jan 6, 2023, 7:15AM
ACCESSWIRE - Dec 14, 2022, 4:25PM
ACCESSWIRE - Nov 16, 2022, 7:30AM
ACCESSWIRE - Nov 11, 2022, 7:20AM
ACCESSWIRE - Nov 10, 2022, 7:15AM
ACCESSWIRE - Aug 18, 2022, 7:40AM
ACCESSWIRE - Aug 18, 2022, 7:15AM
ACCESSWIRE - May 25, 2022, 7:55AM
ACCESSWIRE - May 25, 2022, 7:45AM
ACCESSWIRE - Apr 28, 2022, 7:50AM
ACCESSWIRE - Apr 22, 2022, 7:15AM
ACCESSWIRE - Apr 21, 2022, 7:15AM
ACCESSWIRE - Apr 11, 2022, 7:15AM
ACCESSWIRE - Mar 30, 2022, 7:15AM
ACCESSWIRE - Mar 1, 2022, 7:15AM
ACCESSWIRE - Feb 22, 2022, 7:00AM
ACCESSWIRE - Feb 10, 2022, 7:20AM
InvestorsObserver - 3 days ago
TipRanks - 5 days ago
InvestorsObserver - 5 days ago
InvestorsObserver - 6 days ago
TipRanks - 6 days ago
InvestorPlace - Jan 26, 2023, 6:06PM
InvestorsObserver - Jan 26, 2023, 6:53AM
InvestorsObserver - Jan 25, 2023, 2:44PM
TipRanks - Jan 23, 2023, 11:05AM
InvestorsObserver - Jan 20, 2023, 10:01AM
TipRanks - Jan 19, 2023, 8:43AM
InvestorsObserver - Jan 19, 2023, 5:51AM
InvestorPlace - Jan 18, 2023, 3:44PM
InvestorsObserver - Jan 18, 2023, 8:00AM
TipRanks - Jan 18, 2023, 12:25AM
InvestorPlace - Jan 17, 2023, 2:01PM
InvestorsObserver - Jan 17, 2023, 11:51AM
InvestorsObserver - Jan 13, 2023, 6:19AM
InvestorsObserver - Jan 12, 2023, 1:16PM
InvestorsObserver - Jan 12, 2023, 5:59AM
InvestorsObserver - Jan 11, 2023, 5:59AM
Seeking Alpha - Jan 10, 2023, 1:05PM
Seeking Alpha - Jan 10, 2023, 8:25AM
InvestorsObserver - Jan 10, 2023, 5:45AM
TipRanks - Jan 9, 2023, 8:38AM
TipRanks - Jan 9, 2023, 8:38AM
Seeking Alpha - Jan 9, 2023, 7:10AM
InvestorsObserver - Jan 9, 2023, 5:46AM
TipRanks - Jan 9, 2023, 2:32AM
TipRanks - Jan 9, 2023, 2:32AM
Seeking Alpha - Jan 6, 2023, 8:45PM
TipRanks - Jan 6, 2023, 1:40PM
TipRanks - Jan 6, 2023, 1:15PM
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Read More

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-27
REV
Q3 2022Est.ActualSurprise
EPS-0.270
REV20.370M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy CureVac (CVAC) stock?

A

You can purchase shares of CureVac (NASDAQ: CVAC) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are CureVac's (CVAC) competitors?

A

There are no as such competitors for CureVac.

Q

What is the target price for CureVac (CVAC) stock?

A

The latest price target for CureVac (NASDAQ: CVAC) was reported by UBS on Thursday, January 19, 2023. The analyst firm set a price target for 18.00 expecting CVAC to rise to within 12 months (a possible 62.75% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for CureVac (CVAC)?

A

The stock price for CureVac (NASDAQ: CVAC) is $11.06 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does CureVac (CVAC) pay a dividend?

A

There are no upcoming dividends for CureVac.

Q

When is CureVac (NASDAQ:CVAC) reporting earnings?

A

CureVac’s Q4 earnings are confirmed for Thursday, April 27, 2023.

Q

Is CureVac (CVAC) going to split?

A

There is no upcoming split for CureVac.

Q

What sector and industry does CureVac (CVAC) operate in?

A

CureVac is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2023 Benzinga | All Rights Reserved